Marilyn E Morris

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7720789/publications.pdf

Version: 2024-02-01

194 papers	8,032 citations	66250 44 h-index	64407 83 g-index
241 all docs	241 docs citations	241 times ranked	9442 citing authors

#	Article	IF	Citations
1	Untargeted metabolomics identifies the potential role of monocarboxylate transporter 6 (MCT6/SLC16A5) in lipid and amino acid metabolism pathways. Pharmacology Research and Perspectives, 2022, 10, e00944.	1.1	6
2	Treatment of Î³-Hydroxybutyrate (GHB) Overdose with the GABA_B Antagonist SGS742. Journal of Pharmacology and Experimental Therapeutics, 2022, , JPET-AR-2022-001108.	1.3	0
3	Î³-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology. AAPS Journal, 2021, 23, 22.	2.2	34
4	Immunoglobulin G Is a Novel Substrate for the Endocytic Protein Megalin. AAPS Journal, 2021, 23, 40.	2.2	7
5	Unconjugated p-cresol activates macrophage macropinocytosis leading to increased LDL uptake. JCI Insight, 2021, 6, .	2.3	5
6	Î³-Hydroxybutyric Acidâ€“Ethanol Drug-Drug Interaction: Reversal of Toxicity with Monocarboxylate Transporter 1 Inhibitors. Journal of Pharmacology and Experimental Therapeutics, 2021, 378, 42-50.	1.3	4
7	Toxicokinetic/Toxicodynamic Interaction Studies in Rats between the Drugs of Abuse Î³-Hydroxybutyric Acid and Ketamine and Treatment Strategies for Overdose. Pharmaceutics, 2021, 13, 741.	2.0	2
8	Drugâ€drug interaction between diclofenac and gammaâ€hydroxybutyric acid. Biopharmaceutics and Drug Disposition, 2021, 42, 351-358.	1.1	1
9	Efflux transporters in cancer resistance: Molecular and functional characterization of breast cancer resistance protein. , 2020, , 67-96.		1
10	Pharmacokinetics of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Mice: Potential Enterohepatic Circulation and Target-Mediated Disposition. Pharmaceutical Research, 2020, 37, 5.	1.7	13
11	Megalin-mediated albumin endocytosis in cultured murine mesangial cells. Biochemical and Biophysical Research Communications, 2020, 529, 740-746.	1.0	8
12	Women in the Pharmaceutical Sciences: Honoring Our Pioneers. AAPS Journal, 2020, 22, 136.	2.2	3
13	Targeting the Choroid Plexuses for Protein Drug Delivery. Pharmaceutics, 2020, 12, 963.	2.0	13
14	In Vitro and In Vivo Efficacy of AZD3965 and Alpha-Cyano-4-Hydroxycinnamic Acid in the Murine 4T1 Breast Tumor Model. AAPS Journal, 2020, 22, 84.	2.2	23
15	Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease. Pharmacological Reviews, 2020, 72, 466-485.	7.1	186
16	Monocarboxylate Transporter 6-Mediated Interactions with Prostaglandin F2Î±: In Vitro and In Vivo Evidence Utilizing a Knockout Mouse Model. Pharmaceutics, 2020, 12, 201.	2.0	10
17	Contribution of Monocarboxylate Transporter 6 to the Pharmacokinetics and Pharmacodynamics of Bumetanide in Mice. Drug Metabolism and Disposition, 2020, 48, 788-795.	1.7	3
18	Characterization and Proteomic-Transcriptomic Investigation of Monocarboxylate Transporter 6 Knockout Mice: Evidence of a Potential Role in Glucose and Lipid Metabolism. Molecular Pharmacology, 2019, 96, 364-376.	1.0	10

#	Article	IF	Citations
19	Treatment of Î³-Hydroxybutyric Acid and Î³-Butyrolactone Overdose with Two Potent Monocarboxylate Transporter 1 Inhibitors, AZD3965 and AR-C155858. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 84-91.	1.3	13
20	Simulation-Based Analysis of the Impact of Renal Impairment on the Pharmacokinetics of Highly Metabolized Compounds. Pharmaceutics, 2019, 11, 105.	2.0	3
21	In Vitro and In Vivo Efficacy of the Monocarboxylate Transporter 1 Inhibitor AR-C155858 in the Murine 4T1 Breast Cancer Tumor Model. AAPS Journal, 2019, 21, 3.	2.2	36
22	Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells. AAPS Journal, 2019, 21, 13.	2.2	58
23	Development and validation of a liquid chromatography tandem mass spectrometry assay for AZD3965 in mouse plasma and tumor tissue: Application to pharmacokinetic and breast tumor xenograft studies. Journal of Pharmaceutical and Biomedical Analysis, 2018, 155, 270-275.	1.4	8
24	Effects of renal impairment on transporterâ€mediated renal reabsorption of drugs and renal drugâ€“drug interactions: A simulationâ€based study. Biopharmaceutics and Drug Disposition, 2018, 39, 218-231.	1.1	8
25	The Drug of Abuse Gamma-Hydroxybutyric Acid Exhibits Tissue-Specific Nonlinear Distribution. AAPS Journal, 2018, 20, 21.	2.2	3
26	Prediction of the Effects of Renal Impairment on Clearance for Organic Cation Drugs that Undergo Renal Secretion: A Simulation-Based Study. Drug Metabolism and Disposition, 2018, 46, 758-769.	1.7	15
27	Increased megalin expression in early type 2 diabetes: role of insulin-signaling pathways. American Journal of Physiology - Renal Physiology, 2018, 315, F1191-F1207.	1.3	22
28	Monocarboxylate Transporter (SLC16A). , 2018, , 3175-3189.		0
29	Quercetin, Morin, Luteolin, and Phloretin Are Dietary Flavonoid Inhibitors of Monocarboxylate Transporter 6. Molecular Pharmaceutics, 2017, 14, 2930-2936.	2.3	30
30	Effect of chronic Î³-hydroxybutyrate (GHB) administration on GHB toxicokinetics and GHB-induced respiratory depression. American Journal of Drug and Alcohol Abuse, 2017, 43, 686-693.	1.1	8
31	SLC and ABC Transporters: Expression, Localization, and Species Differences at the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers. AAPS Journal, 2017, 19, 1317-1331.	2.2	104
32	Î³-Hydroxybutyric Acid (GHB) Pharmacokinetics and Pharmacodynamics: Semi-Mechanistic and Physiologically Relevant PK/PD Model. AAPS Journal, 2017, 19, 1449-1460.	2.2	4
33	A quantitative threshold for high/low extent of urinary excretion of compounds in humans. Biopharmaceutics and Drug Disposition, 2016, 37, 287-309.	1.1	11
34	Monocarboxylate Transporters: Therapeutic Targets and Prognostic Factors in Disease. Clinical Pharmacology and Therapeutics, 2016, 100, 454-463.	2.3	86
35	Monoclonal Antibody Pharmacokinetics in Type 2 Diabetes Mellitus and Diabetic Nephropathy. Current Pharmacology Reports, 2016, 2, 45-56.	1.5	32
36	Novel high/low solubility classification methods for new molecular entities. International Journal of Pharmaceutics, 2016, 511, 111-126.	2.6	43

#	Article	IF	Citations
37	Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat. AAPS Journal, 2015, 17, 965-975.	2.2	15
38	A Novel Monocarboxylate Transporter Inhibitor as a Potential Treatment Strategy for Î³-Hydroxybutyric Acid Overdose. Pharmaceutical Research, 2015, 32, 1894-1906.	1.7	24
39	Quantitative Structure-Pharmacokinetic Relationships for the Prediction of Renal Clearance in Humans. Drug Metabolism and Disposition, 2015, 43, 73-81.	1.7	29
40	An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats. AAPS Journal, 2015, 17, 1464-1474.	2.2	5
41	Semi-mechanistic kidney model incorporating physiologically-relevant fluid reabsorption and transporter-mediated renal reabsorption: pharmacokinetics of Î³-hydroxybutyric acid and l-lactate in rats. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 497-513.	0.8	13
42	Effect of 3,4-Methylenedioxymethamphetamine on the Toxicokinetics and Sedative Effects of the Drug of Abuse, Î³-Hydroxybutyric Acid. Journal of Pharmaceutical Sciences, 2014, 103, 3310-3315.	1.6	2
43	Flavonoids Are Inhibitors of Human Organic Anion Transporter 1 (OAT1)â€“Mediated Transport. Drug Metabolism and Disposition, 2014, 42, 1357-1366.	1.7	37
44	Mechanistic Modeling of Monocarboxylate Transporter-Mediated Toxicokinetic/Toxicodynamic Interactions Between Î³-Hydroxybutyrate and l-Lactate. AAPS Journal, 2014, 16, 756-770.	2.2	8
45	Pharmacokinetics and Pharmacodynamics of Phenethyl Isothiocyanate: Implications in Breast Cancer Prevention. AAPS Journal, 2014, 16, 705-713.	2.2	24
46	Role of Monocarboxylate Transporters in Drug Delivery to the Brain. Current Pharmaceutical Design, 2014, 20, 1487-1498.	0.9	270
47	Brain Extracellular Î³-hydroxybutyrate Concentrations are Decreased by L-lactate in Rats: Role in the Treatment of Overdoses. Pharmaceutical Research, 2013, 30, 1338-1348.	1.7	17
48	Mechanistic Models Describing Active Renal Reabsorption and Secretion: A Simulation-Based Study. AAPS Journal, 2013, 15, 278-287.	2.2	17
49	Toxicokinetics/Toxicodynamics ofÎ³-Hydroxybutyrate-Ethanol Intoxication: Evaluation of Potential Treatment Strategies. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 504-513.	1.3	20
50	Chemopreventive and antiâ€angiogenic effects of dietary phenethyl isothiocyanate in an Nâ€methyl nitrosoureaâ€induced breast cancer animal model. Biopharmaceutics and Drug Disposition, 2013, 34, 98-106.	1.1	20
51	Effects of Monocarboxylate Transporter Inhibition on the Oral Toxicokinetics/Toxicodynamics of Î³-Hydroxybutyrate and Î³-Butyrolactone. Journal of Pharmacology and Experimental Therapeutics, 2013, 345, 102-110.	1.3	19
52	Î³-Hydroxybutyrate (GHB)-Induced Respiratory Depression: Combined Receptor-Transporter Inhibition Therapy for Treatment in GHB Overdose. Molecular Pharmacology, 2012, 82, 226-235.	1.0	43
53	Reevaluation of a Quantitative Structure Pharmacokinetic Model for Biliary Excretion in Rats. Drug Metabolism and Disposition, 2012, 40, 1259-1262.	1.7	5
54	Brain Uptake of the Drug of Abuse Î³-Hydroxybutyric Acid in Rats. Drug Metabolism and Disposition, 2012, 40, 212-218.	1.7	33

#	Article	IF	Citations
55	Î³-Hydroxybutyrate Blood/Plasma Partitioning: Effect of Physiologic pH on Transport by Monocarboxylate Transporters. Drug Metabolism and Disposition, 2012, 40, 64-69.	1.7	26
56	A Physiologically Based Pharmacokinetic Model of Mitoxantrone in Mice and Scale-up to Humans: a Semi-Mechanistic Model Incorporating DNA and Protein Binding. AAPS Journal, 2012, 14, 352-364.	2.2	24
57	Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration. AAPS Journal, 2012, 14, 559-570.	2.2	253
58	Noninvasive Real-Time Fluorescence Imaging of the Lymphatic uptake of BSAâ€“IRDye 680 Conjugate Administered Subcutaneously in Mice. Journal of Pharmaceutical Sciences, 2012, 101, 1744-1754.	1.6	10
59	Pharmacokinetics, Lymph Node Uptake, and Mechanistic PK Model of Near-Infrared Dye-Labeled Bevacizumab After IV and SC Administration in Mice. AAPS Journal, 2012, 14, 252-261.	2.2	31
60	Fluorescence Imaging of the Lymph Node Uptake of Proteins in Mice after Subcutaneous Injection: Molecular Weight Dependence. Pharmaceutical Research, 2012, 29, 1843-1853.	1.7	58
61	Influence of Route of Administration and Liposomal Encapsulation on Blood and Lymph Node Exposure to the Protein VEGF-C156S. Journal of Pharmaceutical Sciences, 2012, 101, 852-859.	1.6	8
62	Interspecies scaling: prediction of human biliary clearance and comparison with QSPKR. Biopharmaceutics and Drug Disposition, 2012, 33, 1-14.	1.1	10
63	Use of a Local Sensitivity Analysis to Inform Study Design Based on a Mechanistic Toxicokinetic Model for Î³-Hydroxybutyric Acid. AAPS Journal, 2011, 13, 240-254.	2.2	9
64	5,7-Dimethoxyflavone and Multiple Flavonoids in Combination Alter the ABCG2-Mediated Tissue Distribution of Mitoxantrone in Mice. Pharmaceutical Research, 2011, 28, 1090-1099.	1.7	20
65	The sulfated conjugate of biochanin A is a substrate of breast cancer resistant protein (ABCG2). Biopharmaceutics and Drug Disposition, 2011, 32, 446-457.	1.1	29
66	Simultaneous determination of the flavonoids robinin and kaempferol in human breast cancer cells by liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 109-113.	1.4	18
67	The Bioflavonoid Kaempferol Is an Abcg2 Substrate and Inhibits Abcg2-Mediated Quercetin Efflux. Drug Metabolism and Disposition, 2011, 39, 426-432.	1.7	70
68	Dietary Phenethyl Isothiocyanate Alters Gene Expression in Human Breast Cancer Cells. Evidence-based Complementary and Alternative Medicine, 2011, 2011, 1-8.	0.5	32
69	Monocarboxylate Transporter Inhibition with Osmotic Diuresis Increases Î³-Hydroxybutyrate Renal Elimination in Humans: A Proof-of-Concept Study. , 2011, 01, 1000105.		14
70	Mechanistic Toxicokinetic Model for Î³-Hydroxybutyric Acid: Inhibition of Active Renal Reabsorption as a Potential Therapeutic Strategy. AAPS Journal, 2010, 12, 407-416.	2.2	27
71	Effects of Single and Multiple Flavonoids on BCRP-Mediated Accumulation, Cytotoxicity and Transport of Mitoxantrone In Vitro. Pharmaceutical Research, 2010, 27, 1296-1308.	1.7	27
72	Biliary excretion in dogs: Evidence for a molecular weight threshold. European Journal of Pharmaceutical Sciences, 2010, 40, 33-37.	1.9	12

#	Article	IF	Citations
73	Effects of the isoflavonoid biochanin A on the transport of mitoxantrone in vitro and in vivo. Biopharmaceutics and Drug Disposition, 2010, 31, 340-350.	1.1	15
74	Interactions between the flavonoid biochanin A and P-glycoprotein substrates in rats: In vitro and in vivo. Journal of Pharmaceutical Sciences, 2010, 99, 430-441.	1.6	38
75	Pharmacokinetics and Biliary Excretion of Mitoxantrone in Rats. Journal of Pharmaceutical Sciences, 2010, 99, 2502-2510.	1.6	4
76	Effect of orally administered phenethyl isothiocyanate on hepatic gene expression in rats. Molecular Nutrition and Food Research, 2010, 54, 1802-1806.	1.5	18
77	HPLC analysis of mitoxantrone in mouse plasma and tissues: Application in a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2010, 51, 750-753.	1.4	38
78	Interference of a sulfate conjugate in quantitative liquid chromatography/tandem mass spectrometry through inâ€source dissociation. Rapid Communications in Mass Spectrometry, 2010, 24, 1817-1819.	0.7	9
79	In vivo modulation of 4E binding protein 1 (4E-BP1) phosphorylation by watercress: a pilot study. British Journal of Nutrition, 2010, 104, 1288-1296.	1.2	25
80	Monocarboxylate Transporter-Mediated Transport of Î³-Hydroxybutyric Acid in Human Intestinal Caco-2 Cells. Drug Metabolism and Disposition, 2010, 38, 441-447.	1.7	31
81	Concentration-Effect Relationships for the Drug of Abuse Î³-Hydroxybutyric Acid. Journal of Pharmacology and Experimental Therapeutics, 2010, 333, 764-771.	1.3	40
82	Herbal Supplement-Based Interactions. , 2010, , 555-584.		3
83	The Drug of Abuse Î³-Hydroxybutyrate Is a Substrate for Sodium-Coupled Monocarboxylate Transporter (SMCT) 1 (SLC5A8): Characterization of SMCT-Mediated Uptake and Inhibition. Drug Metabolism and Disposition, 2009, 37, 1404-1410.	1.7	47
84	Comparison of the Effects of Phenethyl Isothiocyanate and Sulforaphane on Gene Expression in Breast Cancer and Normal Mammary Epithelial Cells. Experimental Biology and Medicine, 2009, 234, 287-295.	1.1	46
85	ABC transporters and isothiocyanates: potential for pharmacokinetic dietâ€“drug interactions. Biopharmaceutics and Drug Disposition, 2009, 30, 335-344.	1.1	36
86	Prediction of Biliary Excretion in Rats and Humans Using Molecular Weight and Quantitative Structureâ€“Pharmacokinetic Relationships. AAPS Journal, 2009, 11, 511-25.	2.2	102
87	Structureâ€“Activity Relationships and Quantitative Structureâ€“Activity Relationships for Breast Cancer Resistance Protein (ABCG2). AAPS Journal, 2009, 11, 541-52.	2.2	53
88	MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells. Molecular Pharmacology, 2009, 75, 1374-1379.	1.0	278
89	Biochanin A Inhibits Breast Cancer Tumor Growth in A Murine Xenograft Model. Pharmaceutical Research, 2008, 25, 2158-63.	1.7	62
90	Pharmacokinetics and Bioavailability of the Flavonoid 7,8-Benzoflavone in Rats. Journal of Pharmaceutical Sciences, 2008, 97, 4546-4556.	1.6	19

#	Article	IF	Citations
91	Quercetin pharmacokinetics in humans. Biopharmaceutics and Drug Disposition, 2008, 29, 205-217.	1.1	207
92	Pharmacokinetic Interaction between the Flavonoid Luteolin and Î³-Hydroxybutyrate in Rats: Potential Involvement of Monocarboxylate Transporters. AAPS Journal, 2008, 10, 47-55.	2.2	40
93	Overview of the Proton-coupled MCT (SLC16A) Family of Transporters: Characterization, Function and Role in the Transport of the Drug of Abuse Î³-Hydroxybutyric Acid. AAPS Journal, 2008, 10, 311-21.	2.2	170
94	Effects of L-Lactate and D-Mannitol on Î³-Hydroxybutyrate Toxicokinetics and Toxicodynamics in Rats. Drug Metabolism and Disposition, 2008, 36, 2244-2251.	1.7	26
95	Flavonoids Modulate Monocarboxylate Transporter-1-Mediated Transport of Î³-Hydroxybutyrate in Vitro and in Vivo. Drug Metabolism and Disposition, 2007, 35, 201-208.	1.7	69
96	The Role of Monocarboxylate Transporter 2 and 4 in the Transport of Î³-Hydroxybutyric Acid in Mammalian Cells. Drug Metabolism and Disposition, 2007, 35, 1393-1399.	1.7	53
97	Real-Time Quantitative Polymerase Chain Reaction for BCRP, MDR1, and MRP1 mRNA Levels in Lymphocytes and Monocytes. Acta Haematologica, 2007, 118, 169-175.	0.7	15
98	Pharmacokinetics and Bioavailability of the Bioflavonoid Biochanin A: Effects of Quercetin and EGCG on Biochanin A Disposition in Rats. Molecular Pharmaceutics, 2007, 4, 865-872.	2.3	72
99	Effects of Flavonoids Genistein and Biochanin A on Gene Expression and Their Metabolism in Human Mammary Cells. Nutrition and Cancer, 2007, 57, 48-58.	0.9	20
100	Effects of the Flavonoid Chrysin on Nitrofurantoin Pharmacokinetics in Rats: Potential Involvement of ABCG2. Drug Metabolism and Disposition, 2007, 35, 268-274.	1.7	89
101	Effects of the flavonoid biochanin A on gene expression in primary human hepatocytes and human intestinal cells. Molecular Nutrition and Food Research, 2007, 51, 317-323.	1.5	9
102	2007 highlights of advances in the pharmaceutical sciences: An American Association of Pharmaceutical Scientists (AAPS) perspective. AAPS Journal, 2007, 9, E219-E226.	2.2	0
103	Monocarboxylate Transporter (MCT) Mediates the Transport of Î³-Hydroxybutyrate in Human Kidney HK-2 cells. Pharmaceutical Research, 2007, 24, 1067-1078.	1.7	36
104	Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats. AAPS Journal, 2006, 8, E433-E442.	2.2	91
105	Characterization of Monocarboxylate Transport in Human Kidney HK-2 Cells. Molecular Pharmaceutics, 2006, 3, 675-685.	2.3	44
106	Flavonoidâ€“drug interactions: Effects of flavonoids on ABC transporters. Life Sciences, 2006, 78, 2116-2130.	2.0	226
107	Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism. Toxicology in Vitro, 2006, 20, 187-210.	1.1	773
108	Effect of Quercetin on the Plasma and Intracellular Concentrations of Saquinavir in Healthy Adults. Pharmacotherapy, 2006, 26, 1255-1261.	1.2	16

#	Article	IF	Citations
109	A high-performance liquid chromatographic method for determination of the niguldipine analogue DHP-014. Biomedical Chromatography, 2006, 20, 48-53.	0.8	1
110	Transport of Î³-Hydroxybutyrate in Rat Kidney Membrane Vesicles: Role of Monocarboxylate Transporters. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 751-761.	1.3	61
111	Efflux Transporters in Drug Excretion. , 2005, , 381-410.		3
112	Liquid chromatographyâ€“tandem mass spectroscopy assay for quercetin and conjugated quercetin metabolites in human plasma and urine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 821, 194-201.	1.2	79
113	Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochemical Pharmacology, 2005, 70, 627-639.	2.0	185
114	Transport of dietary phenethyl isothiocyanate is mediated by multidrug resistance protein 2 but not P-glycoprotein. Biochemical Pharmacology, 2005, 70, 640-647.	2.0	32
115	Pharmacokinetics and bioavailability of a newly synthesized dihydropyridine compound with multidrug resistance reversal activity. Biopharmaceutics and Drug Disposition, 2005, 26, 279-285.	1.1	4
116	Effects of New 4-Aryl-1,4-Dihydropyridines and 4-Arylpyridines on Drug Efflux Mediated by Multidrug Resistance-Associated Protein 1. Journal of Pharmaceutical Sciences, 2005, 94, 2256-2265.	1.6	17
117	Pharmacokinetics of Î±-Naphthyl Isothiocyanate in Rats. Journal of Pharmaceutical Sciences, 2005, 94, 2441-2451.	1.6	6
118	Pharmacokinetics of Dietary Phenethyl Isothiocyanate in Rats. Pharmaceutical Research, 2005, 22, 1658-1666.	1.7	96
119	Quantitative Structureâ€“Activity Relationship and Quantitative Structureâ€“Pharmacokinetics Relationship of 1,4-Dihydropyridines and Pyridines as Multidrug Resistance Modulators. Pharmaceutical Research, 2005, 22, 1989-1996.	1.7	20
120	EFFECTS OF DIHYDROPYRIDINES AND PYRIDINES ON MULTIDRUG RESISTANCE MEDIATED BY BREAST CANCER RESISTANCE PROTEIN: IN VITRO AND IN VIVO STUDIES. Drug Metabolism and Disposition, 2005, 33, 1220-1228.	1.7	60
121	FLAVONOIDS AS A NOVEL CLASS OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP1B1 (OATP-C) MODULATORS. Drug Metabolism and Disposition, 2005, 33, 1666-1672.	1.7	137
122	Renal Clearance of Î³-Hydroxybutyric Acid in Rats: Increasing Renal Elimination as a Detoxification Strategy. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 1194-1202.	1.3	55
123	Membrane Transport of Dietary Phenethyl Isothiocyanate by ABCG2 (Breast Cancer Resistance Protein). Molecular Pharmaceutics, 2005, 2, 414-419.	2.3	23
124	NEW 4-ARYL-1,4-DIHYDROPYRIDINES AND 4-ARYLPYRIDINES AS P-GLYCOPROTEIN INHIBITORS. Drug Metabolism and Disposition, 2005, 33, 321-328.	1.7	70
125	FLAVONOIDS CHRYSIN AND BENZOFLAVONE, POTENT BREAST CANCER RESISTANCE PROTEIN INHIBITORS, HAVE NO SIGNIFICANT EFFECT ON TOPOTECAN PHARMACOKINETICS IN RATS OR MDR1A/1B (â€“/â€“) MICE. Drug Metabolism and Disposition, 2005, 33, 341-348.	1.7	89
126	Flavonoids Are Inhibitors of Breast Cancer Resistance Protein (ABCG2)-Mediated Transport. Molecular Pharmacology, 2004, 65, 1208-1216.	1.0	339

#	Article	IF	Citations
127	Combined Effects of Multiple Flavonoids on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport. Pharmaceutical Research, 2004, 21, 1263-1273.	1.7	119
128	Effect of Organic Isothiocyanates on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport. Pharmaceutical Research, 2004, 21, 2261-2269.	1.7	40
129	Effects of Benzylâ€, Phenethylâ€, and Î±â€•naphthyl Isothiocyanates on Pâ€glycoproteinâ€•and MRP1â€mediated Transport. Journal of Pharmaceutical Sciences, 2004, 93, 1901-1911.	1.6	48
130	Dietary Organic Isothiocyanates are Cytotoxic in Human Breast Cancer MCF-7 and Mammary Epithelial MCF-12A Cell Lines. Experimental Biology and Medicine, 2004, 229, 835-842.	1.1	86
131	Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharmaceutical Research, 2003, 20, 1184-1191.	1.7	104
132	Effect of Flavonoids on MRP1-Mediated Transport in Panc-1 Cells. Journal of Pharmaceutical Sciences, 2003, 92, 250-257.	1.6	114
133	Determination of phenethyl isothiocyanate in human plasma and urine by ammonia derivatization and liquid chromatographyâ€“tandem mass spectrometry. Analytical Biochemistry, 2003, 323, 39-47.	1.1	81
134	Determination of Î±-naphthylisothiocyanate and metabolites Î±-naphthylamine and Î±-naphthylisocyanate in rat plasma and urine by high-performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 788, 17-28.	1.2	8
135	Gender Differences in the Membrane Transport of Endogenous and Exogenous Compounds. Pharmacological Reviews, 2003, 55, 229-240.	7.1	119
136	Effects of the Flavonoids Biochanin A, Morin, Phloretin, and Silymarin on P-Glycoprotein-Mediated Transport. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 1258-1267.	1.3	318
137	Choline Uptake in Human Intestinal Caco-2 Cells Is Carrier-Mediated. Journal of Nutrition, 2003, 133, 2607-2611.	1.3	32
138	Effect of organic isothiocyanates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine. Pharmaceutical Research, 2002, 19, 1509-1515.	1.7	53
139	A rapid spectrofluorimetric technique for determining drug-serum protein binding suitable for high-throughput screening. Pharmaceutical Research, 2000, 17, 632-637.	1.7	67
140	Molecular Mechanisms of Renal Sulfate Regulation. Critical Reviews in Clinical Laboratory Sciences, 2000, 37, 345-388.	2.7	6
141	Hormonal Regulation of Sodium/Sulfate Coâ€Transport in Renal Epithelial Cells. Proceedings of the Society for Experimental Biology and Medicine, 2000, 225, 49-57.	2.0	1
142	Rapid Solubility Determination Using Vapor-Phase Osmometry. Journal of Biomolecular Screening, 1999, 4, 315-318.	2.6	5
143	Modulation of sulfate renal transport by alterations in cell membrane fluidity. Journal of Pharmaceutical Sciences, 1999, 88, 976-980.	1.6	17
144	Effect of Pregnancy, Postnatal Growth, and Gender on Renal Sulfate Transport. Proceedings of the Society for Experimental Biology and Medicine, 1999, 221, 336-344.	2.0	15

#	Article	IF	Citations
145	Functional Expression of P-Glycoprotein in the Hepatic Canalicular Membrane of Developing Rats â€. Journal of Pharmaceutical Sciences, 1998, 87, 300-305.	1.6	10
146	Salicylic Acid Induces Changes in the Physical Properties of Model and Native Kidney Membranes. Journal of Pharmaceutical Sciences, 1997, 86, 199-204.	1.6	26
147	Membrane transport in hepatic clearance of drugs. I: Extended hepatic clearance models incorporating concentration-dependent transport and elimination processes. , 1997, 14, 774-779.		10
148	Membrane transport in hepatic clearance of drugs. II: Zonal distribution patterns of concentration-dependent transport and elimination processes. , 1997, 14, 780-785.		9
149	Hepatic conjugation/deconjugation cycling pathways. Computer simulations examining the effect of michaelis-menten parameters, enzyme distribution patterns, and a diffusional barrier on metabolite disposition. Journal of Pharmacokinetics and Pharmacodynamics, 1996, 24, 219-243.	0.6	8
150	Inhibitors of P-Glycoprotein-Mediated Daunomycin Transport in Rat Liver Canalicular Membrane Vesicles. Journal of Pharmaceutical Sciences, 1996, 85, 935-939.	1.6	27
151	Hepatic membrane transport of organic cations using isolated rat hepatocyte membrane vesicles: structure-transport relationships. Pharmaceutical Research, 1995, 12, 1109-1114.	1.7	3
152	Effects of acute caffeine ingestion and menopause on sulfate homeostasis in women. Life Sciences, 1995, 57, 1497-1505.	2.0	12
153	Nonlinear Pharmacokinetics and Protein Binding of Tiaprofenic Acid in Female Lewis Rats. Journal of Pharmaceutical Sciences, 1993, 82, 429-430.	1.6	3
154	Sulfate homeostasis. IV. Probenecid-induced alterations of inorganic sulfate in rats. Pharmaceutical Research, 1991, 08, 376-379.	1.7	4
155	Evaluation of "true" creatinine clearance in rats reveals extensive renal secretion. Pharmaceutical Research, 1991, 08, 1318-1322.	1.7	50
156	Sulfate homeostasis. III. Effect of chronic naproxen or sulindac treatment on inorganic sulfate disposition in arthritic patients with renal impairment. Pharmaceutical Research, 1991, 08, 242-246.	1.7	7
157	High-performance liquid chromatographic analysis of p-nitrophenol and its conjugates in biological samples. Biomedical Applications, 1990, 532, 285-293.	1.7	15
158	Sulfate homeostasis. II. Influence of chronic aspirin administration on inorganic sulfate in humans. Pharmaceutical Research, 1990, 07, 719-722.	1.7	8
159	Magnesium Cerebrospinal Fluid Concentrations and Protein Binding in Magnesium-Deficient Rats. Journal of Pharmaceutical Sciences, 1990, 79, 458-459.	1.6	4
160	N-Acetylator variability in Down's syndrome: Characterization with caffeine. Clinical Pharmacology and Therapeutics, 1989, 46, 359-366.	2.3	5
161	Effect of an Analgesic Dose of Aspirin on Electrolyte Disposition in Healthy Subjects. Journal of Pharmaceutical Sciences, 1988, 77, 814-815.	1.6	1
162	Assay of inorganic sulfate in biologic fluids by nonsuppressed (single-column) ion chromatography. Analytical Biochemistry, 1988, 172, 16-21.	1.1	15

#	Article	IF	Citations
163	Competing pathways in drug metabolism. II. An identical, anterior enzymic distribution for 2- and 5-sulfoconjugation and a posterior localization for 5-glucuronidation of gentisamide in the rat liver. Journal of Pharmacokinetics and Pharmacodynamics, 1988, 16, 633-656.	0.6	20
164	Absorption of Magnesium from Orally Administered Magnesium Sulfate in Man. Journal of Toxicology: Clinical Toxicology, 1987, 25, 371-382.	1.5	19
165	Competition between two enzymes for substrate removal in liver: Modulating effects due to substrate recruitment of hepatocyte activity. Journal of Pharmacokinetics and Pharmacodynamics, 1987, 15, 473-496.	0.6	35
166	Effect of Acetaminophen on Inorganic Sulfate Concentrations in Human Cerebrospinal Fluid. Journal of Pharmaceutical Sciences, 1986, 75, 722-723.	1.6	3
167	Pharmacodynamics of the Hypnotic Effect of Salicylamide in Rats. Journal of Pharmaceutical Sciences, 1985, 74, 599-602.	1.6	2
168	Renal Clearance and Serum Protein Binding of Acetaminophen and Its Major Conjugates in Humans. Journal of Pharmaceutical Sciences, 1984, 73, 1038-1041.	1.6	36
169	Serum concentration and renal excretion by normal adults of inorganic sulfate after acetaminophen, ascorbic acid, or sodium sulfate. Clinical Pharmacology and Therapeutics, 1983, 33, 529-536.	2.3	71
170	Determination of Salicylamide and Five Metabolites in Biological Fluids by High-Performance Liquid Chromatography. Journal of Pharmaceutical Sciences, 1983, 72, 612-617.	1.6	22
171	Absorption of Sulfate from Orally Administered Magnesium Sulfate in Man. Journal of Toxicology: Clinical Toxicology, 1983, 20, 107-114.	1.5	27
172	Oral contraceptive-induced ischemic bowel disease. American Journal of Health-System Pharmacy, 1979, 36, 1103-1107.	0.5	4
173	Incompatibility of diazepam injection in plastic intravenous bags. American Journal of Health-System Pharmacy, 1979, 36, 505-507.	0.5	6
174	Analgesic activity of floctafenine after cholecystectomy. Clinical Pharmacology and Therapeutics, 1978, 23, 383-389.	2.3	2
175	Compatibility and Stability of Diazepam Injection Following Dilution with Intravenous Fluids. American Journal of Health-System Pharmacy, 1978, 35, 669-672.	0.5	13
176	Multidrug Resistance Proteins of the ABCC Subfamily. , 0, , 263-318.		7
177	Organic Anion Transporters. , 0, , 51-73.		0
178	Drug Transport in the Liver. , 0, , 359-410.		7
179	Drug Transporters in the Intestine. , 0, , 495-515.		1
180	Polymorphisms of Drug Transporters and Clinical Relevance. , 0, , 619-663.		0

#	Article	IF	Citations
181	Age- and Gender-Related Differences in Xenobiotic Transporter Expression. , 0, , 589-617.		0
182	Regulation of Drug Transporter Activity. , 0, , 517-531.		0
183	Experimental Approaches to the Study of Drug Transporters. , 0, , 533-556.		0
184	Diet/Nutrient Interactions with Drug Transporters. , 0, , 665-708.		3
185	Clinical Relevance: Drugâ€“Drug Interactions, Pharmacokinetics, Pharmacodynamics, and Toxicity. , 0, , 747-880.		5
186	Interplay of Drug Transporters and Enzymes on Hepatic Drug Processing. , 0, , 709-745.		3
187	In Vitroâ€“In Vivo Scale-up of Drug Transport Activities. , 0, , 557-588.		9
188	Overview of Drug Transporter Families. , 0, , 1-10.		2
189	Organic Anionâ€“Transporting Polypeptides. , 0, , 75-104.		7
190	Monocarboxylate Transporters. , 0, , 147-170.		1
191	Wiley Series in Drug Discovery and Development. , 0, , 890-890.		1
192	Organic Cation/Carnitine Transporters. , 0, , 35-50.		0
193	Nucleoside Transporters: CNTs and ENTs. , 0, , 171-200.		0
194	Drug Transport in the Kidney. , 0, , 463-493.		4